{"title":"FBXO32通过调控NME1促进胃癌进展。","authors":"Xiong-Hui Rao, Huaiyu Qiu, Weifei Zhang, Nuoqing Weng, Xiaobin Wu","doi":"10.21037/tcr-2024-2426","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer, a common cancer, has a high incidence rate, the 5-year survival rate of gastric cancer with distant metastasis is less than 10%, so finding new targets for gastric cancer is of clinical importance. As a member of the F-box protein family, F-box protein 32 (FBXO32) plays a role in various cancers, but its role in gastric cancer is currently unclear, this study mainly focused on the role and mechanism of FBXO32 in gastric cancer.</p><p><strong>Methods: </strong>The FBXO32 expression was found through The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. The FBXO32 expression in cell lines was found through Western blot assay. Cell cloning assay and Cell Counting Kit-8 (CCK8) assay were used to investigate the effect of FBXO32 on gastric cancer cell proliferation. Wound-healing assay and transwell assay were used to research the effect of FBXO32 on gastric cancer cell metastasis. Cancer stem cell sphere-forming assay was used to find out the effect of FBXO32 on the stemness of gastric cancer cells. Nude mouse tumorigenesis assay was used to investigate the effect of FBXO32 on gastric cancer tumor growth.</p><p><strong>Results: </strong>It was found that FBXO32 expression is elevated in gastric cancer, which is associated with poor prognosis. In addition, FBXO32 expression is also elevated in gastric cancer cell lines. The knockdown of FBXO32 can inhibit the proliferation, migration, invasion and stemness of gastric cancer cells, inhibit the subcutaneous tumor formation of gastric cancer cells in nude mice, and increase the expression of non-metastatic cells 1 (NME1). Low expression of NME1 is associated with poor prognosis in gastric cancer. The knockdown of NME1 expression can offset part of the tumor suppressor activity of the knockdown of FBXO32.</p><p><strong>Conclusions: </strong>It is believed that FBXO32 promotes the progression of gastric cancer by regulating NME1. Most importantly, our findings could provide information for the mechanism of gastric cancer and the discovery of new targets.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 6","pages":"3520-3531"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268887/pdf/","citationCount":"0","resultStr":"{\"title\":\"FBXO32 promotes gastric cancer progression by regulating NME1.\",\"authors\":\"Xiong-Hui Rao, Huaiyu Qiu, Weifei Zhang, Nuoqing Weng, Xiaobin Wu\",\"doi\":\"10.21037/tcr-2024-2426\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Gastric cancer, a common cancer, has a high incidence rate, the 5-year survival rate of gastric cancer with distant metastasis is less than 10%, so finding new targets for gastric cancer is of clinical importance. As a member of the F-box protein family, F-box protein 32 (FBXO32) plays a role in various cancers, but its role in gastric cancer is currently unclear, this study mainly focused on the role and mechanism of FBXO32 in gastric cancer.</p><p><strong>Methods: </strong>The FBXO32 expression was found through The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. The FBXO32 expression in cell lines was found through Western blot assay. Cell cloning assay and Cell Counting Kit-8 (CCK8) assay were used to investigate the effect of FBXO32 on gastric cancer cell proliferation. Wound-healing assay and transwell assay were used to research the effect of FBXO32 on gastric cancer cell metastasis. Cancer stem cell sphere-forming assay was used to find out the effect of FBXO32 on the stemness of gastric cancer cells. Nude mouse tumorigenesis assay was used to investigate the effect of FBXO32 on gastric cancer tumor growth.</p><p><strong>Results: </strong>It was found that FBXO32 expression is elevated in gastric cancer, which is associated with poor prognosis. In addition, FBXO32 expression is also elevated in gastric cancer cell lines. The knockdown of FBXO32 can inhibit the proliferation, migration, invasion and stemness of gastric cancer cells, inhibit the subcutaneous tumor formation of gastric cancer cells in nude mice, and increase the expression of non-metastatic cells 1 (NME1). Low expression of NME1 is associated with poor prognosis in gastric cancer. The knockdown of NME1 expression can offset part of the tumor suppressor activity of the knockdown of FBXO32.</p><p><strong>Conclusions: </strong>It is believed that FBXO32 promotes the progression of gastric cancer by regulating NME1. Most importantly, our findings could provide information for the mechanism of gastric cancer and the discovery of new targets.</p>\",\"PeriodicalId\":23216,\"journal\":{\"name\":\"Translational cancer research\",\"volume\":\"14 6\",\"pages\":\"3520-3531\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268887/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tcr-2024-2426\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2024-2426","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
FBXO32 promotes gastric cancer progression by regulating NME1.
Background: Gastric cancer, a common cancer, has a high incidence rate, the 5-year survival rate of gastric cancer with distant metastasis is less than 10%, so finding new targets for gastric cancer is of clinical importance. As a member of the F-box protein family, F-box protein 32 (FBXO32) plays a role in various cancers, but its role in gastric cancer is currently unclear, this study mainly focused on the role and mechanism of FBXO32 in gastric cancer.
Methods: The FBXO32 expression was found through The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. The FBXO32 expression in cell lines was found through Western blot assay. Cell cloning assay and Cell Counting Kit-8 (CCK8) assay were used to investigate the effect of FBXO32 on gastric cancer cell proliferation. Wound-healing assay and transwell assay were used to research the effect of FBXO32 on gastric cancer cell metastasis. Cancer stem cell sphere-forming assay was used to find out the effect of FBXO32 on the stemness of gastric cancer cells. Nude mouse tumorigenesis assay was used to investigate the effect of FBXO32 on gastric cancer tumor growth.
Results: It was found that FBXO32 expression is elevated in gastric cancer, which is associated with poor prognosis. In addition, FBXO32 expression is also elevated in gastric cancer cell lines. The knockdown of FBXO32 can inhibit the proliferation, migration, invasion and stemness of gastric cancer cells, inhibit the subcutaneous tumor formation of gastric cancer cells in nude mice, and increase the expression of non-metastatic cells 1 (NME1). Low expression of NME1 is associated with poor prognosis in gastric cancer. The knockdown of NME1 expression can offset part of the tumor suppressor activity of the knockdown of FBXO32.
Conclusions: It is believed that FBXO32 promotes the progression of gastric cancer by regulating NME1. Most importantly, our findings could provide information for the mechanism of gastric cancer and the discovery of new targets.
期刊介绍：
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
